 GARDEN CITY, N.Y., May 26, 2021 GLOBE NEWSWIRE -- Beyond Air, Inc. NASDAQ: XAIR, a clinical-stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide NO for the treatment of patients with respiratory conditions, including serious lung infections and pulmonary hypertension, and gaseous NO gNO for the treatment of solid tumors, today announced an agreement with former LungFit PH commercial licensee, Circassia Group plc. Under the terms of the agreement, Beyond Air retains United States and China commercialization rights to LungFit PH in exchange for returning upfront and milestone payments received by the Company in 2019, along with capped future royalty payments. Beyond Air now holds full global rights to LungFit PH. 